At AbbVie, we strive to develop innovative medicines that will help people live better lives in the future. For Allergan Healthcare legacy providers, patients, and caregivers, we offer a convenient inquiry form. We also welcome your comments on our social media channels, but please remember that we operate in a highly regulated industry with specific legal requirements. Before participating, please read and follow our established community guidelines for each channel.
Links that take you away from AbbVie websites around the world are not under our control, and we are not responsible for the content of those sites or any other links from those sites. We provide these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by AbbVie. Allergan plc is an American pharmaceutical company based in Ireland that acquires, develops, manufactures, and markets brand-name drugs and medical devices in the areas of medical aesthetics, eye care, central nervous system, and gastroenterology. The company is best known for creating Botox.
It became a public company through an initial public offering in 1977. In 1991, Allergan acquired Oculinum, a company that manufactured products for ocular muscle disorders. After the acquisition, the product was renamed Botox. In 1996, Allergan received FDA approval for Alphagan ophthalmic solution for open-angle glaucoma and ocular hypertension. Two years later, they established The Allergan Foundation, a private charitable foundation based in the United States.
Since then, Allergan has acquired several companies including Auden Mckenzie Holdings Limited (Acq 201), Furiex Pharmaceuticals Inc (Acq 201), Procter & Gamble (Prescription Drug Div, Acq 200), and Specifar Pharmaceuticals S. A.
